Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR84 | Q9NQS5 | 7/20 | 0.68 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.68 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | LCK | P06239 | 1/20 | 0.48 |
| ▸ | PPARD | Q03181 | 1/20 | 0.48 |
| ▸ | ZDHHC20 | Q5W0Z9 | 1/20 | 0.48 |
| ▸ | ZDHHC2 | Q9UIJ5 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1783714 | 1.00 | GPR84 (0.68) | GPR84FFAR1FFAR4MAPTLCK | |
| SCHEMBL1782851 | 1.00 | GPR84 (0.68) | GPR84FFAR1FFAR4MAPTLCK | |
| SCHEMBL669623 | 1.00 | GPR84 (0.68) | GPR84FFAR1FFAR4MAPTLCK | |
| SCHEMBL1785430 | 1.00 | GPR84 (0.68) | GPR84FFAR1FFAR4MAPTLCK | |
| SCHEMBL6494854 | 1.00 | GPR84 (0.68) | GPR84FFAR1FFAR4MAPTLCK | |
| SCHEMBL1783344 | 1.00 | GPR84 (0.68) | GPR84FFAR1FFAR4MAPTLCK | |
| SCHEMBL15867154 | 1.00 | GPR84 (0.68) | GPR84FFAR1FFAR4MAPTLCK | |
| SCHEMBL1786126 | 1.00 | GPR84 (0.68) | GPR84FFAR1FFAR4MAPTLCK | |
| SCHEMBL1785014 | 1.00 | GPR84 (0.68) | GPR84FFAR1FFAR4MAPTLCK | |
| SCHEMBL28558495 | 1.00 | GPR84 (0.68) | GPR84FFAR1FFAR4MAPTLCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8632792-B2 | Cooling sensation agent composition and sensory stimulation agent composition | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2014-01-21 | — | — | US | disclosed |
| US-20110117147-A1 | COOLING SENSATION AGENT COMPOSITION AND SENSORY STIMULATION AGENT COMPOSITION | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2011-05-19 | — | — | US | disclosed |
| WO-2009123355-A2 | COOLING SENSATION AGENT COMPOSITION AND SENSORY STIMULATION AGENT COMPOSITION | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2009-10-08 | — | — | WO | disclosed |
| EP-1358144-B1 | EPOTHILONE SYNTHESIS COMPONENTS I: ASYMMETRICALLY SUBSTITUTED ACYLOINS AND ACYLOIN DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND METHOD FOR THE PRODUCTION OF EPITHILONE AND EPOTHILONE DERIVATIVES | R & D BIOPHARMACEUTICALS (DE) | 2006-12-27 | — | — | EP | disclosed |
| US-6867333-B2 | EPOTHILONE SYNTHESIS BUILDING BLOCKS III AND IV: ASYMMETRICALLY SUBSTITUTED ACYLOINS AND ACYLOIN DERIVATIVES, METHODS FOR THEIR PRODUCTION AND METHODS FOR THE PRODUCTION OF EPOTHILONES B, D AND EPOTHILONE DERIVATIVES | MORPHOCHEM AG (DE) | 2005-03-15 | — | — | US | disclosed |
| US-20040082651-A1 | Epothilone synthesis building blocks III and IV: asymmetrically substituted acyloins and acyloin derivatives, methods for their production and methods for the production of epothilones B, D and epothilone derivatives | R & D BIOPHARMACEUTICALS GMBH (DE) | 2004-04-29 | — | — | US | disclosed |
| EP-1358144-A1 | EPOTHILONE SYNTHESIS COMPONENTS III AND IV: ASYMMETRICALLY SUBSTITUTED ACYLOINS AND ACYLOIN DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND METHOD FOR THE PRODUCTION OF EPITHILONE B, D AND EPOTHILONE DERIVATIVES | Morphochem AG (DE) | 2003-11-05 | — | — | EP | disclosed |
| EP-1357193-A1 | Preparation of pyrazines | SOCIETE DES PRODUITS NESTLE S.A. (CH) | 2003-10-29 | — | — | EP | disclosed |
| WO-2002032844-A2 | EPOTHILONE SYNTHESIS COMPONENTS III AND IV: ASYMMETRICALLY SUBSTITUTED ACYLOINS AND ACYLOIN DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND METHOD FOR THE PRODUCTION OF EPITHILONE B, D AND EPOTHILONE DERIVATIVES | MORPHOCHEM AG (DE) | 2002-04-25 | — | — | WO | disclosed |
| EP-0473206-B1 | Compositions containing a terminal-modified block copolymer | ASAHI CHEMICAL IND (JP) | 1999-06-23 | — | — | EP | disclosed |
| US-5332784-A | Conjugated diene, vinylaromatic copolymer | ASAHI KASEI KOGYO KABUSHIKI KAISHA (JP) | 1994-07-26 | — | — | US | disclosed |
| US-5115035-A | Modified block copolymer of conjugated diene and vinylaromatic and a tackifier resin | ASAHI KASEI KOGYO KABUSHIKI KAISHA (JP) | 1992-05-19 | — | — | US | disclosed |
| EP-0473206-A2 | Compositions containing a terminal-modified block copolymer | Asahi Kasei Kogyo Kabushiki Kaisha (JP) | 1992-03-04 | — | — | EP | disclosed |
| EP-0245505-A1 | TERMINAL-MODIFIED BLOCK COPOLYMER AND COMPOSITION CONTAINING SAID COPOLYMER | Asahi Kasei Kogyo Kabushiki Kaisha (JP) | 1987-11-19 | — | — | EP | disclosed |
| US-3952024-A | FLAVOR ADDITIVE FOR FOODS AND BEVERAGES | FIRMENICH & CIE (CH) | 1976-04-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110117147-A1 | COOLING SENSATION AGENT COMPOSITION AND SENSORY STIMULATION AGENT COMPOSITION | TRPA1, HRH1, HRH2 | GPR84 77/4885FFAR1 229/4885FFAR4 319/4885 |
| US-20040082651-A1 | Epothilone synthesis building blocks III and IV: asymmetrically substituted acyloins and acyloin derivatives, methods for their production and methods for the production of epothilones B, D and epothilone derivatives | COASY, ACOX1, FDFT1 | GPR84 3411/4885FFAR1 2120/4885FFAR4 992/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.